3-(2-fluoro-4-pyridinyl)-5-[4-morpholin-4-yl-3-[(2S)-pyrrolidin-2-yl]phenyl]pyridin-2-amine
C24H26FN5O — CID 155426021
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(2-fluoro-4-pyridinyl)-5-[4-morpholin-4-yl-3-[(2S)-pyrrolidin-2-yl]phenyl]pyridin-2-amine
3-(2-fluoro-4-pyridinyl)-5-[4-morpholin-4-yl-3-[(2S)-pyrrolidin-2-yl]phenyl]pyridin-2-amine (PubChem CID 155426021) has the molecular formula C24H26FN5O and a molecular weight of 419.50 g/mol. Its IUPAC name is 3-(2-fluoro-4-pyridinyl)-5-[4-morpholin-4-yl-3-[(2S)-pyrrolidin-2-yl]phenyl]pyridin-2-amine.
Molecular Properties
| Compound Name | 3-(2-fluoro-4-pyridinyl)-5-[4-morpholin-4-yl-3-[(2S)-pyrrolidin-2-yl]phenyl]pyridin-2-amine |
|---|---|
| PubChem CID | 155426021 |
| Molecular Formula | C24H26FN5O |
| Molecular Weight | 419.50 g/mol |
| Exact Mass | 419.21 |
| IUPAC Name | 3-(2-fluoro-4-pyridinyl)-5-[4-morpholin-4-yl-3-[(2S)-pyrrolidin-2-yl]phenyl]pyridin-2-amine |
| SMILES | Nc1ncc(-c2ccc(N3CCOCC3)c([C@@H]3CCCN3)c2)cc1-c1ccnc(F)c1 |
| InChI | InChI=1S/C24H26FN5O/c25-23-14-17(5-7-28-23)19-13-18(15-29-24(19)26)16-3-4-22(30-8-10-31-11-9-30)20(12-16)21-2-1-6-27-21/h3-5,7,12-15,21,27H,1-2,6,8-11H2,(H2,26,29)/t21-/m0/s1 |
| InChIKey | MSVLCANBLDKCRF-NRFANRHFSA-N |
| XLogP | 3.79 |
| TPSA | 76.30 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 419.50 |
| LogP ≤ 5 | 3.79 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': '2-halo_pyridine', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155426021 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.